Moderna MRNA Stand-ready manufacturing revenue — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Moderna in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Moderna’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Moderna's stand-ready manufacturing revenue — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Moderna's stand-ready manufacturing revenue — total revenue?
- Moderna (MRNA) reported stand-ready manufacturing revenue — total revenue of $32M in Q1 2026.
- How has Moderna's stand-ready manufacturing revenue — total revenue changed year-over-year?
- Moderna's stand-ready manufacturing revenue — total revenue increased by 166.7% year-over-year, from $12M to $32M.
- What does stand-ready manufacturing revenue — total revenue mean?
- This metric represents revenue generated from contractual arrangements where the company maintains manufacturing capacity or readiness for a partner or client. It reflects the monetization of specialized infrastructure and operational preparedness rather than the direct sale of finished therapeutic products. This revenue stream is typically associated with long-term strategic partnerships or government contracts that prioritize supply chain security and manufacturing agility.